Products Elexacaftor was approved in the United States in 2019 and in many countries in 2020 as a fixed-dose combination with tezacaftor and ivacaftor in film-coated tablet form (Trikafta). In the morning dose, all three active ingredients are included. In the evening dose, only ivacaftor. Structure and properties Elexacaftor (C26H34F3N7O4S, Mr = 597.7 g/mol) exists … Elexacaftor
Products Lumacaftor is commercially available in a fixed combination with the CFTR potentiator ivacaftor in the form of film-coated tablets (Orkambi). The drug was approved in the EU and US in 2015 and in many countries in 2016. Structure and properties Lumacaftor (C24H18F2N2O5, Mr = 452.4 g/mol) exists as a white powder that is practically … Lumacaftor
Products Tezacaftor was approved in the US and EU in 2018 and in many countries in 2019 in fixed combination with previously registered ivacaftor in film-coated tablet form (Symdeko). In 2020, a fixed combination with tezacaftor, elexacaftor, and ivacaftor was approved (Trikafta). Structure and properties Tezacaftor (C26H27F3N2O6, Mr = 520.5 g/mol) exists as a white … Tezacaftor